The PennZone

  • Home
  • Non-profit
  • Music
  • Books
  • Marketing
  • Entertainment
  • Health
  • Automotive
  • Legal

ExpressCells to Present in BIO Start-Up Stadium Next Week
The PennZone/10070540

Trending...
  • Pregis Launches Sharp InfinX: On-Demand Rightsized Mailing System Delivering a Precision-Sized Mailer for Every Order
  • netElastic Announces vBNG And CGNAT 2.0 General Availability
  • Claude Zdanow named Managing Director in Miami, Florida
Company is one of 30 selected for prestigious competition. During BIO Digital Week, attendees can watch timely, on-demand pitches and meet with ExpressCells via BIO's One-on-One Partnering.

PHILADELPHIA - PennZone -- ExpressCells, Inc. (ExpressCells), a privately-owned genetic engineering company that creates knock-in cell lines for drug discovery, will be one of the finalists presenting in the Start-Up Stadium during BIO Digital Week.

"We are honored to be selected by the judges as one of the finalists for Start-Up Stadium. We hope that all BIO Digital Week attendees view our presentation, which will be available on demand via the meeting platform."

Start-Up Stadium provides an exciting and interactive experience where key stakeholders of the early-stage life science community, investors, and strategic partners provide feedback and judge 6 minute pitches presented by start-up biotech companies. During BIO Digital Week, attendees can watch ExpressCells' pitch on-demand and meet with the company via BIO's One-on-One Partnering.

More on The PennZone
  • Roots for Boots to Participate in 2026 Adams County Community Foundation Giving Spree
  • Timbrana Helps General Contractors Improve Jobsite Visibility and Subcontractor Accountability
  • Citizens for West Virginia Election Integrity Urges "FOR" on Amendment 1
  • Vegan Kingz Expands Direct-Import Wholesale Lineup to Help Commercial Kitchens Cut Ingredient Costs
  • Acuvance Survey Finds ERP Integration Remains a Key Challenge as Healthcare Organizations Prepare for AI

"ExpressCells is excited to be part of BIO Digital Week," Mr. Handel continued. "We hope to gain valuable feedback and to meet with both potential customers and potential investors.

About ExpressCells

ExpressCells is a private biotechnology company based in Philadelphia, PA. Its propriety genome editing technology, in combination with CRISPR/Cas9, creates advanced, knock-in cell line up to 75% faster than older processes. This technology allows ExpressCells to insert up to three genes into the same cell line.

ExpressCells' first knock-in cell lines code for bioluminescent and fluorescent proteins. These allow scientists to more see the results of their experiments in real time. ExpressCells sells both custom cell lines—each designed to meet the specific requirements of an individual scientist—and catalog cell lines. For more information, visit www.xpresscells.com.

Contact
Matthew Handel
***@xpresscells.com
+1 (484) 483-6759


Source: ExpressCells, Inc.

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • JFAB Consulting to Celebrate New Brand with Private VIP Event at Acrisure Stadium
  • Industrial & systems engineering educator and professional to lead global strategic partnerships for professional society
  • Convergence of AI, Wearable Technology, Remote Patient Monitoring and Real-World Healthcare: PomDoctor Ltd. (N A S D A Q: POM)
  • Timbrana — Construction Project Awareness Software for General Contractors
  • Service Guys Urges Ontario Homeowners to Book Chimney Cleaning and WETT Inspections Before the 2026 Heating Season
  • WOWX Completes Its Transition from CEX to Decentralized Derivatives Infrastructure
  • HSS Medical Supply Celebrates One-Year Anniversary of Its Top Performing Sales Team
  • Jacombs Tickets Partners with UEFA to Offer Champions League Tickets
  • Corner Property Management Awarded Management Contract with Clock Towers Condominium Association
  • WebDrafter Welcomes Honey in the Hollow as a New Marketing Client
  • Geospatial Innovation Comes to Sacramento: FOSS4G NA 2026
  • Tulsa Air & Space Museum Launches "Give $16 for the F-16" Challenge to Bring Thunderbird Home for Veterans Day
  • Hannk And Zubie Join Forces To Shape The Next Generation Of Connected Vehicle Telematics
  • Coinfiliate Launches Platform to Helps Shoppers Earn Cashback and Creators Earn Referral Rewards
  • Champions for Education to Honor United Way of the Greater Lehigh Valley and Induct Three Leaders
  • Holiday Gambling Spending Expected to Rise 12% in December
  • RAS AP Consulting Issues National Compliance Alert and Launches Q4 2026 AP Readiness Program Ahead of IRS FIRE → IRIS Cutover
  • Free Senior Housing Webinar Helps Families Plan for Aging Before a Crisis Forces Difficult Decisions
  • Claude Zdanow named Managing Director in Miami, Florida
  • YWCA Hanover Celebrates Opening of New Children's Learning Academy

Popular on PennZone

  • Dion Abadi Publishes Free Collector Tips Hub for Art and Jewelry Buyers
  • UVIFY Brings Advanced Autonomous Systems Research to IROS 2026 in Pittsburgh
  • Garage door installation or repair in Minnesota? Which makes more sense for your family?
  • Subject matter experts: Present your ideas at IISE Annual Conference 2027 in Louisville
  • Can Government Operate Better Through Innovation?
  • Her Song Lives On: Remembering Mrs. Darlene Davis Porter
  • New Metallized PE Film from Pregis Brings Recyclability to High-Barrier Food Packaging at Pack Expo International in Chicago
  • Most Indiana Plane Crashes Happen Away from the State's Major Airports
  • Keystone Consulting Engineers Expands into Brodheadsville, Strengthening Regional Engineering
  • Put Your Herd on Your Phone: Kiko Nation Makes Livestock Management Simple

Similar on PennZone

  • Danish company biosuite introduces biotech procurement software to track outsourced R&D commitments
  • $11.18 Million DARPA Award Ignites a Major New Catalyst as FDA, Robotic TMS and Commercialization Milestones Converge for NRx Pharmaceuticals, Inc
  • Nutriband (N A S D A Q: NTRB): Fighting Back Against the Fentanyl Crisis With a New Approach to Safer Transdermal Medicines
  • Most Utah Deaths Never Reach the Medical Examiner. Postmortem Pathology Offers Salt Lake City a Private Autopsy Option
  • Nutriband Inc. (N A S D A Q: NTRB) Breaks Into Uncharted Territory: 52-Week High Eclipsed as Shares Surge 22% —AVERSA™ Puts Investors on High Alert
  • Thar Process Partners with French Leader ExtrateX to Bring Prep to Process-Scale SFC to Europe
  • Biophysical Therapeutics brings longevity science to skincare with its new IF1 brand
  • ClearSight Therapeutics Receives NIH SBIR Phase I Award for Conjunctivitis and EKC Research
  • Lunai Bioworks (N A S D A Q: LNAI) Takes Parkinson's Discovery to the Next Level With Exclusive Tanaist Agreement
  • Independent Autopsies Are Changing Civil Cases: Kansas City Forensic Explains Why Families Are Seeking Second Opinions
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us